DARA BioSciences Announces Sales Force Expansion and Agreement With Mission Pharmacal in the Oncology Market

DARA BioSciences Announces Sales Force Expansion and Agreement With Mission 
Pharmacal in the Oncology Market 
Signs Agreement, Exclusive to Oncology Market, With Mission
Pharmacal; Signs Agreement With Alamo Pharma Services for a National
Sales Team to Promote DARA's Products With Three Additional Mission
Supportive Care Products; Results of Increased Sales Frequency
Support National Field Force Expansion 
RALEIGH, NC  -- (Marketwired) -- 10/28/13 --  DARA BioSciences, Inc.
(NASDAQ: DARA), an oncology supportive care pharmaceutical company
dedicated to providing health care professionals a synergistic
portfolio of medicines to help cancer patients adhere to therapy and
manage side effects arising from cancer treatment, today announced
the signing of an agreement with Alamo Pharma Services, a subsidiary
of Mission Pharmacal, for a twenty (20) person national sales team in
the U.S. oncology market. Pursuant to the agreement and a shared
sales force agreement with Mission, the Alamo sales team in addition
to promoting Dara's products Soltamox® (tamoxifen citrate), Gelclair®
and Bionect® will also carry three Mission Pharmacal products:
Ferralet® 90 (for anemia), BINOSTO® (alendronate sodium effervescent
tablet indicated for the treatment of osteoporosis), and Aquoral®
(for chemotherapy/radiation therapy-induced dry mouth). The
agreements with Alamo and Mission expand DARA's presence in oncology
supportive care to address ongoing areas of unmet medical need. 
DARA implemented a refined commercial strategy at the end of Q2 2013,
realigning the original sales force of five (5) representatives to
smaller territories, thereby increasing sales call frequency to
targeted high volume customers. The outcome of this refinement was a
significant increase in product sales in Q3 2013 compared with the
previous quarter. Increasing the field sales organization, through
its partnership with Alamo Pharma Services, is expected to continue
to drive this product momentum and provide the necessary scope and
coverage of high prescribing oncologists maximizing the potential of
DARA's product portfolio. 
The combined product and commercial expansion are both integral parts
of DARA's long-term strategy to become the leader in the field of
oncology supportive care. The Company expects to have the sales force
trained and in the field by January 1, 2014. 
David J. Drutz, MD, DARA Biosciences' Chief Executive Officer and
Chief Medical Officer, said, "Our partnerships with Mission Pharmacal
and Alamo Pharma Services are both extremely significant for DARA.
These relationships allow us to immediately expand the needed
commercial infrastructure to support a robust field sales
organization in the field of oncology supportive care. The agreement
with Alamo gives DARA the opportunity to complement our current
product portfolio of Soltamox®, Gelclair® and Bionect® providing a
truly unique and complementary offering that will benefit patients
suffering from cancer and the debilitating side effects associated
with their cancer treatments. The shared sales force can provide a
formidable product portfolio that addresses many of the common side
effects that cancer patients deal with on a daily basis, including
oral mucositis, loss of bone density, chemoradiation dermatitis, dry
mouth, anemia, and preference or need for an oral liquid medicine."  
Terry Herring, President of both Mission Pharmacal Commercial
Division and Alamo Pharma Services, said, "Providing high level sales
teams to successful organizations is of primary importance to Alamo
Pharma Services. This unique opportunity with DARA BioSciences
presents Mission Pharmacal Company and our diverse product portfolio
a pathway into the Oncology space. This collaboration demonstrates
flexibility with all three organizations in the evolving healthcare
market, and DARA's strong existing portfolio provides us a high level
of executional confidence. Incorporating existing Mission products
that have proven successful in other markets into an expanded
offering is a win-win for both companies. We are truly excited by the
potential of our partnership." 
Aligning with Mission Pharmacal and Alamo will significantly enhance
the effectiveness of DARA's commercial capabilities and builds
solidly upon DARA's supportive care focus with physicians and
patients. DARA now has a tremendous opportunity to realize the full
potential of its commercial portfolio, and these agreements provide
the company with a broader platform to unlock current and future
value.  
About Mission Pharmacal Company 
Mission Pharmacal Company is a privately held pharmaceutical company
based in San Antonio, Texas. For more than 65 years, the company has
been committed to meeting the unique healthcare needs of women
throughout all stages of life, pediatric patients, and those persons
dealing with urologic and dermatologic conditions. The company has a
proven track record of identifying unmet healthcare needs and
developing both innovative prescription and over-the-counter products
to meet these needs. Using only the purest ingredients and
FDA-approved methods of manufacturing, Mission Pharmacal provides
physicians and consumers with the highest quality pharmaceutical and
dietary supplement products on the market today. Mission Pharmacal is
a proud national supporter of the March of Dimes Foundation, whose
mission is to improve the health of babies by preventing birth
defects, premature birth, and infant mortality. For full prescribing
information on all of Mission's drugs or for more information about
the company, visit missionpharmacal.com. 
About Alamo  
Alamo Pharma Services was founded in 2011 as a vehicle for Mission
Pharmacal Company to operate its sales teams. Through outsourced
partnerships and internal capabilities, Alamo Pharma Services offers
pharmaceutical and biotech companies a viable commercial solution
partner to either co-market with existing teams or launch a
stand-alone team. Alamo Pharma Services has the capability to manage
the entire recruiting, hiring, training and ongoing operational
support of the sales team. For more information about the company,
visit alamopharmaservices.com. 
About DARA BioSciences, Inc. 
DARA BioSciences Inc. is an oncology supportive care pharmaceutical
company dedicated to providing healthcare professionals a synergistic
portfolio of medicines to help cancer patients adhere to their
therapy and manage side effects arising from their cancer treatments. 
DARA holds exclusive U.S. marketing rights to Soltamox (tamoxifen
citrate) oral solution, the only liquid form of tamoxifen, used for
the treatment and prevention of breast cancer. Soltamox offers a
choice to patients who prefer or need a liquid form of tamoxifen.
Gelclair is an alcohol-free bioadherent oral rinse gel for rapid and
effective relief of pain associated with oral mucositis caused by
chemotherapy and radiation treatment. DARA licensed the U.S. rights
to Soltamox from UK-based Rosemont Pharmaceuticals, Ltd., and
Gelclair from the Helsinn Group in Switzerland. Under an agreement
with Innocutis, DARA also markets Bionect (hyaluronic acid sodium
salt, 0.2%) a topical treatment for skin irritation and burns
associated with radiation therapy, in U.S. oncology/radiology
markets.  
DARA is focused on expanding its portfolio of oncology supportive
care products in the United States, via in-licensing and/or
partnering of complementary late-stage and approved products. In
addition, the company wishes to identify a strategic partner for the
clinical development of KRN5500, currently in Phase 2 for the
treatment of chronic, treatment refractory, chemotherapy induced
peripheral neuropathy (CCIPN). The FDA has designated KRN5500 as a
Fast Track Drug, and DARA is seeking orphan status for the treatment
of CCIPN. For more information about the Company, visit
www.darabio.com. 
Safe Harbor Statement 
All statements in this news release that are not historical are
forward-looking statements within the meaning of the Securities
Exchange Act of 1934, as amended. Such forward-looking statements are
subject to factors that could cause actual results to differ
materially for DARA from those projected. Important factors that
could cause actual results to differ materially from the expectations
described in these forward-looking statements are set forth under the
caption "Risk Factors" in DARA's most recent Annual Report on Form
10-K, filed with the SEC on March 28, 2013. Those factors include
risks and uncertainties relating to DARA's ability to timely
commercialize and generate revenues or profits from Bionect®,
Soltamox®, Gelclair® or other products given that DARA only recently
hired its initial sales force and DARA's lack of history as a
revenue-generating company, DARA's ability to achieve the desired
results from the agreements with Mission and Alamo, FDA and other
regulatory risks relating to DARA's ability to market Bionect,
Soltamox, Gelclair or other products in the United States or
elsewhere, DARA's ability to in-license and/or partner products,
DARA's current cash position and its need to raise additional capital
in order to be able to continue to fund its operations, the current
regulatory environment in which DARA sells its products, the market
acceptance of those products, dependence on partners, successful
performance under collaborative and other commercial agreements,
competition, the strength of DARA's intellectual property and the
intellectual property of others, the potential delisting of DARA's
common stock from the NASDAQ Capital Market, risks and uncertainties
relating to DARA's ability to successfully integrate Oncogenerix and
other risk factors identified in the documents DARA has filed, or
will file, with the Securities and Exchange Commission ("SEC").
Copies of DARA's filings with the SEC may be obtained from the SEC
Internet site at http://www.sec.gov. DARA expressly disclaims any
obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in DARA's expectations with regard thereto or any
change in events, conditions, or circumstances on which any such
statements are based. DARA BioSciences and the DARA logo are
trademarks of DARA BioSciences, Inc. 
Media Contacts: 
David Connolly or Samantha Stenbeck
LaVoie Group
617-374-8800
dconnolly@lavoiegroup.com    
sstenbeck@lavoiegroup.com  
Corporate Contact:
Jenene Thomas
DARA BioSciences
908-938-1475
jthomas@darabio.com   
Mission Pharmacal/Alamo Pharma Services Contact
Drew Deeter
DEETER Strategic Public Relations
215-348-3890
drew@deterusa.com  
 
 
Press spacebar to pause and continue. Press esc to stop.